Pharmacological Treatment of Obesity in Older Adults
Open accessThe DOI matches its Crossref record; 77 of the 79 references it cites were found in a registry or an index.
Abstract
Obesity is a complex health issue with growing prevalence worldwide. It is also becoming more prevalent in the population of older adults (i.e., 65 years of age and older), affecting frequency and severity as well as other comorbidities, quality of life and consequently, life expectancy. In this article we review currently available data on pharmacotherapy of obesity in the population of older adults and its role in obesity management. Even though there is growing evidence, in particular in the general population, of favourable efficacy and safety profiles of glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and semaglutide, and recently dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide, concise guidelines for older adults are not available to this day. We further discuss specific approaches to frequently represented phenotype of obesity in older adults, in particular sarcopenic obesity and rationale when to treat and how. In older adults with obesity there is a need for more drug trials focusing not only on weight loss, but also on geriatric endpoints including muscle mass preservation, bone quality and favourable fat distribution changes to get enough data for evidence-based recommendation on obesity treatment in this growing sub-population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the most common adverse events (AEs) of treatment are mild to moderate gastrointestinal including nausea, vomiting, diarrhea, constipation, dyspepsia, and decreased appetite.”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AEs are more frequent in older adults compared to young adults, and they are particularly noted to occur during dose escalation [12, 43, 57, 75].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, evidence regarding its use in individuals aged 65 years and older remains limited [12].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [12]
In the citing paper
“These effects were consistent across participants aged ≥ 65 and < 65 years [12, 43].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818 · cited 2×
“Sarcopenia is a progressive and generalised skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability and mortality [16].”
BackgroundOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 2×
“Total lean body mass also decreased in absolute terms; the proportion of lean body mass relative to total body mass increased after treatment with semaglutide [60].”
BackgroundMethodInfluentialTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“The ratio of total fat mass to total lean mass decreased more with tirzepatide (from 0.93 at baseline to 0.70 at week 72) compared with placebo (from 0.95 to 0.88) [71].”
BackgroundInfluentialA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Health and economic burden of the projected obesity trends in the USA and the UK
Wang, Y. C., McPherson, K., Marsh, T., Gortmaker, S. L., & Brown, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60814-3 · Cited by 2,692
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382 · cited 4×
“Meta-analysis [21] of 33 intervention studies lasting 8–24 weeks reported that calorie restriction alone without resistance training leads to the loss of muscle mass and loss of handgrip strength [11, 21].”
BackgroundInfluentialSARC-F: A simple questionnaire to rapidly diagnose sarcopenia
Malmstrom, T. K., & Morley, J. E. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.05.018 · Cited by 1,319
Overview of Epidemiology and Contribution of Obesity to Cardiovascular Disease
Bastien, M., Poirier, P., Lemieux, I., & Després, J.-P. (2014) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2013.10.016 · Cited by 1,125
Weight loss, exercise, or both and physical function in obese older adults
Villareal, D. T., Chode, S., Parimi, N., Sinacore, D. R., Hilton, T., Armamento-Villareal, R., Napoli, N., Qualls, C., & Shah, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008234 · Cited by 1,096 · cited 2×
“…adults ≥ 65 years with obesity (BMI ≥ 30 kg/m 2 ) led to a marked loss of lean mass at 1 year (3.2 ± 2.0 kg, 5% change from baseline) compared with the diet and exercise group, where the loss of lean mass was partially mitigated (decrease of 1.8 ± 1.7 kg, 3% change from baseline); ( p = 0.04) [22].”
BackgroundInfluentialRosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., et al. (2022) · Obesity Facts · doi:10.1159/000521241 · Cited by 1,019
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947
BMI and all-cause mortality in older adults: a meta-analysis
Winter, J. E., MacInnis, R. J., Wattanapenpaiboon, N., & Nowson, C. A. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.068122 · Cited by 790
(1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00690.x · Cited by 758
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
Pati, S., Irfan, W., Jameel, A., Ahmed, S., & Shahid, R. K. (2023) · Cancers · doi:10.3390/cancers15020485 · Cited by 677
Treatment of Obesity: Weight Loss and Bariatric Surgery
Wolfe, B. M., Kvach, E., & Eckel, R. H. (2016) · Circulation Research · doi:10.1161/circresaha.116.307591 · Cited by 648
Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2021.11.014 · Cited by 566
ESPEN practical guideline: Clinical nutrition and hydration in geriatrics
Volkert, D., Beck, A. M., Cederholm, T., Cruz-Jentoft, A., Hooper, L., Kiesswetter, E., Maggio, M., Raynaud-Simon, A., Sieber, C., Sobotka, L., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.01.024 · Cited by 516 · cited 3×
“Physical exercise should accompany every weight-reducing intervention if possible alongside with proper nutritional support [33].”
BackgroundInfluentialGLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
Review: Diabetes, Obesity, and Cancer—Pathophysiology and Clinical Implications
Lega, I. C., & Lipscombe, L. L. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz014 · Cited by 364
English, W. J., DeMaria, E. J., Hutter, M. M., Kothari, S. N., Mattar, S. G., Brethauer, S. A., & Morton, J. M. (2020) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2019.12.022 · Cited by 363
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343
Heymsfield, S. B., Coleman, L. A., Miller, R., Rooks, D. S., Laurent, D., Petricoul, O., Praestgaard, J., Swan, T., Wade, T., Perry, R. G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.33457 · Cited by 338
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332 · cited 1×
“A 48-week phase 2 clinical trial led to 20.5% reduction of fat mass (compared with 0.5% in placebo group) and increased lean mass by 3.6% in contrast to − 0.8% with placebo ( p 0.001) [93, 94].”
MethodInfluentialBatsis, J. A., Barre, L. K., Mackenzie, T. A., Pratt, S. I., Lopez‐Jimenez, F., & Bartels, S. J. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12260 · Cited by 330
Finer, N., James, W., Kopelman, P., Lean, M., & Williams, G. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801128 · Cited by 325
A Review of the Important Role of CYP2D6 in Pharmacogenomics
Taylor, C., Crosby, I., Yip, V., Maguire, P., Pirmohamed, M., & Turner, R. M. (2020) · Genes · doi:10.3390/genes11111295 · Cited by 316
Min, T., & Bain, S. C. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00981-0 · Cited by 285
Mathus-Vliegen, E. M. H., Basdevant, A., Finer, N., Hainer, V., Hauner, H., Micic, D., Maislos, M., Roman, G., Schutz, Y., Tsigos, C., et al. (2012) · Obesity Facts · doi:10.1159/000341193 · Cited by 261
Current technologies in body composition assessment: advantages and disadvantages
Ceniccola, G. D., Castro, M. G., Piovacari, S. M. F., Horie, L. M., Corrêa, F. G., Barrere, A. P. N., & Toledo, D. O. (2019) · Nutrition · doi:10.1016/j.nut.2018.11.028 · Cited by 252
Stephenson, J., Smith, C. M., Kearns, B., Haywood, A., & Bissell, P. (2021) · BMC Public Health · doi:10.1186/s12889-021-12009-8 · Cited by 209
Uchitomi, R., Oyabu, M., & Kamei, Y. (2020) · Nutrients · doi:10.3390/nu12103189 · Cited by 193
Bosello, O., & Vanzo, A. (2021) · Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity · doi:10.1007/s40519-019-00815-4 · Cited by 186
Contribution of Obesity to International Differences in Life Expectancy
Preston, S. H., & Stokes, A. (2011) · American Journal of Public Health · doi:10.2105/ajph.2011.300219 · Cited by 185
Exercise Prescriptions in Older Adults.
Lee, P. G., Jackson, E. A., & Richardson, C. R. (2017) · PubMed · Cited by 183
Weight loss in obese adults 65years and older: A review of the controversy
Waters, D. L., Ward, A. L., & Villareal, D. T. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.02.005 · Cited by 176
Obesity Paradox: Fact or Fiction?
Simati, S., Kokkinos, A., Dalamaga, M., & Argyrakopoulou, G. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00497-1 · Cited by 169
The role of bariatric surgery to treat diabetes: current challenges and perspectives
Koliaki, C., Liatis, S., le Roux, C. W., & Kokkinos, A. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0202-6 · Cited by 167
Liraglutide and obesity: a review of the data so far
Ladenheim, E. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s58459 · Cited by 146
Perna, S., Guido, D., Bologna, C., Solerte, S. B., Guerriero, F., Isu, A., & Rondanelli, M. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-015-0525-y · Cited by 125 · cited 1×
“…weeks treatment with 3.0 mg of liraglutide was associated with reduction of fat mass and preserved skeletal muscle mass in nine individuals with both overweight or obesity and type 2 diabetes with mean age of 68.22 ± 3.86 years with base-line lack of physical activity and sedentary lifestyle [49].”
MethodInfluentialCosta, R., Oliveira, N. G., & Dinis-Oliveira, R. J. (2019) · Drug Metabolism Reviews · doi:10.1080/03602532.2019.1620763 · Cited by 124
Impact of overweight, obesity and severe obesity on life expectancy of Australian adults
Lung, T., Jan, S., Tan, E. J., Killedar, A., & Hayes, A. (2019) · International Journal of Obesity · doi:10.1038/s41366-018-0210-2 · Cited by 108
Vitamin D deficiency in elderly: Risk factors and drugs impact on vitamin D status
Kweder, H., & Eidi, H. (2018) · Avicenna Journal of Medicine · doi:10.4103/ajm.ajm_20_18 · Cited by 106
Liraglutide for Type 2 diabetes and obesity: a 2015 update
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1054810 · Cited by 101
GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
Xiang, J., Qin, L., Zhong, J., Xia, N., & Liang, Y. (2023) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s425642 · Cited by 100
Obesity in the geriatric population – a global health perspective
Malenfant, J. H., & Batsis, J. A. (2019) · Journal of Global Health Reports · doi:10.29392/joghr.3.e2019045 · Cited by 92
Weight Loss, Exercise, or Both and Physical Function in Obese Older Adults
Villareal, D. T., Chode, S., Parimi, N., Sinacore, D. R., Hilton, T., Armamento-Villareal, R., Napoli, N., Qualls, C., & Shah, K. (2011) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e3182352181 · Cited by 83
Onakpoya, I. J., Lee, J. J., Mahtani, K. R., Aronson, J. K., & Heneghan, C. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14210 · Cited by 75
Associations of sarcopenic obesity versus sarcopenia alone with functionality
Bahat, G., Kilic, C., Ozkok, S., Ozturk, S., & Karan, M. A. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.04.002 · Cited by 73
Warren, M., Chaykin, L., Trachtenbarg, D., Nayak, G., Wijayasinghe, N., & Cariou, B. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13331 · Cited by 70
Evaluation of efficacy and safety of orlistat in obese patients
Jain, S., Ramanand, S., Ramanand, J., Akat, P., Patwardhan, M., & Joshi, S. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.81938 · Cited by 69
Zhi, J., Moore, R., Kanitra, L., & Mulligan, T. E. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003252236 · Cited by 65
Gilbert, M. P., Bain, S. C., Franek, E., Jodar-Gimeno, E., Nauck, M. A., Pratley, R., Réa, R. R., Kerr Saraiva, J. F., Rasmussen, S., Tornøe, K., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-1569 · Cited by 62
Dynapenic Obesity and Lower Extremity Function in Elderly Adults
Yang, M., Jiang, J., Hao, Q., Luo, L., & Dong, B. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.06.019 · Cited by 61 · cited 1×
“Low handgrip strength and elevated BMI were strongly associated with an increased risk of functional decline compared with obesity and dynap-enia alone [20].”
BackgroundOrlistat Enhances Warfarin Effect
MacWalter, R. S., Fraser, H. W., & Armstrong, K. M. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c122 · Cited by 58
Özkök, S., Aydın, Ç. Ö., Sacar, D. E., Çatıkkaş, N. M., Erdoğan, T., Bozkurt, M. E., Kılıç, C., Karan, M. A., & Bahat, G. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.09.005 · Cited by 55
Zibellini, J., Seimon, R. V., Lee, C. M. Y., Gibson, A. A., Hsu, M. S. H., & Sainsbury, A. (2016) · Obesity Reviews · doi:10.1111/obr.12422 · Cited by 54 · cited 1×
“Meta-analysis [21] of 33 intervention studies lasting 8–24 weeks reported that calorie restriction alone without resistance training leads to the loss of muscle mass and loss of handgrip strength [11, 21].”
BackgroundUchiyama, S., Sada, Y., Mihara, S., Sasaki, Y., Sone, M., & Tanaka, Y. (2023) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4987 · Cited by 52
Liraglutide restores impaired associative learning in individuals with obesity
Hanssen, R., Rigoux, L., Kuzmanovic, B., Iglesias, S., Kretschmer, A. C., Schlamann, M., Albus, K., Edwin Thanarajah, S., Sitnikow, T., Melzer, C., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00859-y · Cited by 52 · cited 1×
“Recently, beneficial effect of liraglutide on impaired associative learning in individuals with obesity was also reported by Hanssen et al. [55].”
BackgroundThe Current Landscape of Pharmacotherapies for Sarcopenia
Bahat, G., & Özkök, S. (2024) · Drugs & Aging · doi:10.1007/s40266-023-01093-7 · Cited by 48
Iranmanesh, P., Boudreau, V., Ramji, K., Barlow, K., Lovrics, O., & Anvari, M. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-01031-w · Cited by 47
Obesity, Sleep Apnea Syndrome, and Rhythmogenic Risk
Grimm, W., & Becker, H. F. (2006) · Herz · doi:10.1007/s00059-006-2800-3 · Cited by 43
Bariatric surgery outcomes in geriatric patients: a contemporary, nationwide analysis
Mabeza, R. M., Mao, Y. V., Maynard, K., Lee, C., Benharash, P., & Yetasook, A. K. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.04.014 · Cited by 36
Pratley, R. E., Aroda, V. R., Catarig, A., Lingvay, I., Lüdemann, J., Yildirim, E., & Viljoen, A. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-037883 · Cited by 31
Prognostic Value of Adipokines in Predicting Cardiovascular Outcome: Explaining the Obesity Paradox
Wolk, R. A., Bertolet, M. H., Singh, P., Brooks, M. M., Pratley, R. E., Frye, R. L., Mooradian, A. D., Rutter, M. K., Calvin, A. D., CHAITMAN, B. R., et al. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.03.020 · Cited by 30
Kiyosue, A., Dunn, J. P., Cui, X., Hickey, A., Hirase, T., Imaoka, T., & Heine, R. J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14952 · Cited by 30 · cited 1×
“At week 52, tirzepatide induced a similar dose-dependent reduction in glycated haemoglobin, waist circumference and BMI across all sub-groups, with similar safety profile in both age groups; only treatment discontinuation was higher in the group 65 years of age and older due to adverse events [73].”
BackgroundAcute oxalate nephropathy associated with orlistat
Humayun, Y., Ball, K. C., Lewin, J. R., Lerant, A. A., & Fülöp, T. (2016) · Journal of Nephropathology · doi:10.15171/jnp.2016.14 · Cited by 29
Yamada, Y., Yabe, D., Hertz, C. L., Horio, H., Nakamura, J., Nielsen, A. M., & Seino, Y. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14571 · Cited by 21
Kim, K. K. (2019) · Korean Journal of Family Medicine · doi:10.4082/kjfm.19.0013 · Cited by 20
Bahat, G., & Özkök, S. (2023) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02326-2 · Cited by 19
Abdalla, M. A., Soyiri, I., Atkin, S., & Sathyapalan, T. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_16_23 · Cited by 8 · cited 1×
“The baseline age for all tirzepatide doses had no significant effect on body weight reduction effect (for tirzepatide 5 mg: p = 0.198, tirzepatide 10 mg: p = 0.600 and tirzepatide 15 mg: p = 0.608) [70].”
BackgroundInfluentialAge no Impediment to Effective Weight Loss with Liraglutide 3.0 Mg: Data from Two Randomized Trials
Rubino, D., Coelho, R., Kahan, S., Kushner, R., Wilding, J., Jepsen, C., Smolarz, G., & Wyatt, H. (2018) · International Journal of Nutrology · doi:10.1055/s-0038-1674366 · Cited by 4
Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes
Tonoike, M., Chujo, D., & Noda, M. (2018) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.43 · Cited by 3
671-P: Liraglutide Possibly Prevents Progression of Dementia in Patients with Type 2 Diabetes
Yoshida, M., Yoshida, A., Oh, E., Yamamoto, N., Sasaki, E., YOSHIDA, S., Ohsawa, N., Sugino, M., & KOYAMA, I. (2021) · Diabetes · doi:10.2337/db21-671-p · Cited by 1
Research works printed but not linked: 3
- Purnell JQ. Definitions, classification, and epidemiology of obesity. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al., editors. Endotext. South Dartmouth, MA: MDText.com, Inc; 2000. 25905390
- Warren MCL, Trachtenbarg D, Nayak G, Wijayasinghe N, Cariou B. Efficacy and safety of once-weekly semaglutide in elderly subjects with type 2 diabetes: post hoc analysis of SUSTAIN 1–5 trials. Diabetologia. 2017;60(Suppl 1):1–608.28795195
- Huecker MR, Smiley A, Saadabadi A. Bupropion. Treasure Island: StatPearls; 2024. 29262173
Cited by
The Gut Microbiome in Human Obesity: A Comprehensive Review
Borrego-Ruiz, A., & Borrego, J. J. (2025) · Biomedicines · doi:10.3390/biomedicines13092173 · Cited by 65
GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101708 · Cited by 28
(2026) · doi:10.1007/s13668-026-00777-x · Cited by 10
Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary?
Chavez, A. M., Barria, R. C., & León-Sanz, M. (2025) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001130 · Cited by 30
Srivastava, G., Campbell, S. L., Hill, C. R., Stanley, T. L., Lawson, E. A., Apovian, C. M., Almandoz, J. P., Leggio, L., Lakdawalla, D. N., Dar, M., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.06.015 · Cited by 5
Metadata
- Authors
- Žižka, O., Haluzík, M., & Jude, E. B.
- Affiliations
- Charles University (CZ)
- Tameside Hospital (GB)
- Corresponding author
- Jude, Edward B.
- ORCID
- Jude, Edward B.
- Venue
- Drugs & Aging
- Published
- 2024-11
- Volume
- 41
- Issue
- 11
- Pages
- 881-896
- ISSN
- 1170-229X (ISSN-L)
- 1179-1969
- PMC
- PMC11554829
- OpenAlex
- W4404195924
- Cited by
- 23
- References
- 79
- Citations by year
- 2026: 11 · 2025: 12
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 7 d)
- Locations
- Drugs & Aging (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Keywords
- obesity, older adults, pharmacotherapy, GLP-1 receptor agonists, liraglutide, semaglutide, tirzepatide, GIP/GLP-1 receptor agonist, sarcopenic obesity, weight loss, muscle mass preservation, bone quality, body fat distribution, drug safety
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Humans, Obesity, Anti-Obesity Agents, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
![Fig. 1 Sarcopenia definition. (Based on criteria from: Sarcopenia: revised European consensus on definition and diagnosis [16].)](https://figures.cochat.ai/paper-figures/0f13db1d008c49a284c8cd17d4d3d15e/pharmacological-treatment-of-obesity-in-older-adults-figure-1.jpg)
